AEON Biopharma, Inc. (AEON): Nasdaq/NYSE listing notice — NYSE American accepts AEON's compliance plan; delisting risk deferred to Aug 2026

AEON Biopharma, Inc.

NYSE American accepted AEON's compliance plan on April 22, 2025, granting until August 3, 2026 to meet listing standards under Sections 1003(a)(i)-(iii).
AEON remains listed on NYSE American under symbol AEON during the Plan Period, subject to periodic progress reviews.
Failure to regain compliance or make sufficient progress by August 3, 2026 may lead to delisting proceedings.
Non-compliance was first disclosed in February 2025; plan submission deadline was March 5, 2025.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AEON Biopharma, Inc. received a nyse_american extension granted notice regarding other (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: extension granted
Rules: 1003(a)(i), 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

April 22, 2025, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Plan was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 3, 2026 (the “Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide d

View on SEC.gov

Browse all listing & compliance notices →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.